vs
Side-by-side financial comparison of NexPoint Real Estate Finance, Inc. (NREF) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $11.1M, roughly 1.7× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs 65.7%, a 150.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -48.8%).
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
NREF vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $18.6M |
| Net Profit | $24.0M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | 216.6% | 65.7% |
| Revenue YoY | -48.8% | 1808.5% |
| Net Profit YoY | 58.7% | 376.5% |
| EPS (diluted) | $0.47 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $18.6M | ||
| Q3 25 | $12.5M | $334.0K | ||
| Q2 25 | $12.1M | $1.4M | ||
| Q1 25 | $11.5M | $257.0K | ||
| Q4 24 | $21.7M | $977.0K | ||
| Q3 24 | $12.5M | $660.0K | ||
| Q2 24 | $6.7M | $736.0K | ||
| Q1 24 | $-12.8M | $1.4M |
| Q4 25 | $24.0M | $12.3M | ||
| Q3 25 | $50.9M | $-8.6M | ||
| Q2 25 | $22.3M | $-6.9M | ||
| Q1 25 | $26.0M | $-5.4M | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $23.3M | $-2.8M | ||
| Q2 24 | $12.1M | $-14.5M | ||
| Q1 24 | $-14.6M | $411.0K |
| Q4 25 | — | 56.3% | ||
| Q3 25 | — | -2516.5% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | — | -1255.0% | ||
| Q1 24 | — | -692.5% |
| Q4 25 | 216.6% | 65.7% | ||
| Q3 25 | 407.0% | -2572.2% | ||
| Q2 25 | 184.5% | -504.8% | ||
| Q1 25 | 225.6% | -2097.7% | ||
| Q4 24 | 69.9% | — | ||
| Q3 24 | 186.4% | -425.5% | ||
| Q2 24 | 179.7% | -1964.4% | ||
| Q1 24 | 114.3% | 29.9% |
| Q4 25 | $0.47 | $0.25 | ||
| Q3 25 | $1.14 | $-0.17 | ||
| Q2 25 | $0.54 | $-0.14 | ||
| Q1 25 | $0.70 | $-0.11 | ||
| Q4 24 | $0.71 | — | ||
| Q3 24 | $0.74 | $-0.06 | ||
| Q2 24 | $0.40 | $-0.30 | ||
| Q1 24 | $-0.83 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.1M | $40.0M |
| Total DebtLower is stronger | $771.2M | — |
| Stockholders' EquityBook value | $388.0M | $49.4M |
| Total Assets | $5.3B | $59.0M |
| Debt / EquityLower = less leverage | 1.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | $40.0M | ||
| Q3 25 | $17.9M | $37.9M | ||
| Q2 25 | $9.1M | $44.8M | ||
| Q1 25 | $19.2M | $40.6M | ||
| Q4 24 | $3.9M | $59.3M | ||
| Q3 24 | $34.7M | $68.8M | ||
| Q2 24 | $4.3M | $73.0M | ||
| Q1 24 | $13.5M | $80.2M |
| Q4 25 | $771.2M | — | ||
| Q3 25 | $720.9M | — | ||
| Q2 25 | $815.6M | — | ||
| Q1 25 | $831.5M | — | ||
| Q4 24 | $799.3M | — | ||
| Q3 24 | $815.5M | — | ||
| Q2 24 | $861.0M | — | ||
| Q1 24 | $843.3M | — |
| Q4 25 | $388.0M | $49.4M | ||
| Q3 25 | $375.4M | $36.4M | ||
| Q2 25 | $348.2M | $44.5M | ||
| Q1 25 | $343.7M | $50.5M | ||
| Q4 24 | $336.5M | $55.1M | ||
| Q3 24 | $335.8M | $58.5M | ||
| Q2 24 | $327.5M | $60.4M | ||
| Q1 24 | $327.1M | $74.1M |
| Q4 25 | $5.3B | $59.0M | ||
| Q3 25 | $5.3B | $51.1M | ||
| Q2 25 | $5.4B | $60.7M | ||
| Q1 25 | $5.4B | $67.9M | ||
| Q4 24 | $5.4B | $90.6M | ||
| Q3 24 | $5.7B | $99.0M | ||
| Q2 24 | $6.6B | $107.8M | ||
| Q1 24 | $7.1B | $118.3M |
| Q4 25 | 1.99× | — | ||
| Q3 25 | 1.92× | — | ||
| Q2 25 | 2.34× | — | ||
| Q1 25 | 2.42× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 2.63× | — | ||
| Q1 24 | 2.58× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.5M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.19× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.5M | $18.4M | ||
| Q3 25 | $8.1M | $-8.7M | ||
| Q2 25 | $3.3M | $-7.5M | ||
| Q1 25 | $16.0M | $-7.5M | ||
| Q4 24 | $4.4M | $-24.0M | ||
| Q3 24 | $14.7M | $765.0K | ||
| Q2 24 | $-7.5M | $-10.9M | ||
| Q1 24 | $17.7M | $-4.0M |
| Q4 25 | -0.19× | 1.50× | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | -0.62× | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NREF
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
